Qujing

This observational, prospective, multi-center registry studies patients treated with Medtronic Neurovascular devices for intracranial aneurysms and acute ischemic stroke. It aims to continuously evaluate and report the safety and effectiveness of these market-approved products in real-world clinical practice. The registry includes patients who receive treatment using specific Medtronic devices under conditions MDT16056 and MDT17077. Participants undergo treatment with Medtronic devices designed either for embolization of intracranial aneurysms or for revascularization of blood vessels affected by acute ischemic stroke. The study involves a single-arm design without randomization, monitoring patients receiving standard device treatments as part of routine care. Data are collected during and after treatment to assess outcomes over time. During the study, participants will be followed up to assess clinical success, defined as complete occlusion of the aneurysm without retreatment or significant artery narrowing at one year, and functional independence measured by the modified Rankin Scale score at 90 days. The registry also collects safety and effectiveness data through periodic reporting. Participation may last up to several years, with follow-up visits scheduled according to the standard care and registry protocol to track outcomes and adverse events.

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Researchers are evaluating whether a real-time, algorithm-driven ventilation feedback system can improve lung-protective ventilation LPV in critically ill patients with acute respiratory distress syndrome ARDS or similar respiratory failure who are receiving invasive mechanical ventilation. The study compares this new technology against standard intensive care unit ICU care, aiming to increase the time patients maintain safe ventilation settings. The main goal is to see if this approach helps reduce ventilator-induced lung injury and improve outcomes over the first 72 hours of ventilation. Participants are randomly assigned to one of two groups the intervention group receives continuous respiratory waveform monitoring via a cloud-based system called RemoteVentilate ViewTM, which provides real-time alerts, 4-hour window checks, and daily summary reports to guide ventilator adjustments. The control group receives usual ICU care with standard ventilator monitoring but without structured feedback. Both groups continue to receive other treatments such as fluid management, sedation, and adjunct respiratory monitoring as decided by their clinical teams. During the study, participants are monitored closely with high-frequency data collection on ventilation parameters and patient-ventilator synchrony. Researchers measure the daily rate of lung-protective ventilation achievement over the first 72 hours, ventilator-free days at 28 days, ICU length of stay, inflammatory markers, and rates of complications like ventilator-associated pneumonia and barotrauma. Usability and workload for clinicians using the feedback system are also assessed. The total study period includes close monitoring throughout ICU care, with outcomes followed up to 28 days after enrollment.

Researchers are studying children with short stature who were born small for gestational age SGA to evaluate the safety and effectiveness of Inpegsomatropin injection compared with recombinant human growth hormone rhGH. This Phase III, multicenter, randomized clinical trial aims to better understand treatment options for growth challenges in this specific group of children aged 2 to under 11 years. Participants are divided into groups based on age and gender and randomized to receive different treatments or standard care. The trial includes three groups two experimental groups receiving different doses of Inpegsomatropin injection 140 mcgkgweek or 280 mcgkgweek, administered subcutaneously once a week for 52 weeks, and an active control group receiving recombinant human growth hormone injection at 0.033 mgkgday, administered subcutaneously once daily for 52 weeks. Before treatment, participants undergo a screening period lasting up to 12 weeks. After the 52-week treatment, there is a 5-week post-treatment follow-up to monitor safety and efficacy. Participants will be closely monitored throughout the study with regular assessments of growth velocity, changes in height, bone age, and insulin-like growth factor 1 levels. Safety evaluations will include checking liver and kidney function and monitoring for adverse effects. The main outcome measured is growth velocity after 52 weeks of treatment. The total time involvement for each participant includes screening, treatment, and follow-up periods, ensuring comprehensive evaluation of treatment impact and safety.